NCT02193152 2020-07-14
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Washington University School of Medicine
Phase 2 Terminated
Clinical Trials
10 trialsNCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01253369 2019-04-23
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01262820 2017-03-07
LCCC0921
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01179269 2016-10-12
Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer
Loyola University
Phase 2 Withdrawn
NCT01027598 2016-01-29
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00549328 2014-11-19
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01049776 2014-09-19
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Illinois CancerCare, P.C.
Phase 2 Terminated
NCT00871403 2013-06-20
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00367679 2012-06-12
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed